Greg Thurber, PhD

Computational models help researchers anticipate how ADCs may behave in later lines of development, while they are still in the early stages.

ADC payloads with high levels of potency can sometimes lead to higher levels of toxicity, which can eliminate the therapeutic window for patients with cancer.

According to Greg Thurber, PhD, target-mediated uptake is the biggest driver of efficacy for antibody-drug conjugates as a cancer treatment.